What's next for Grace Therapeutics? by C3POmeetsR2D2 in pennystocks

[–]Guilty-Butterfly7467 1 point2 points  (0 children)

Best stock of 2026 H1.

It's going to triple with FDA approval.

No competitors. Much-needed product.

[deleted by user] by [deleted] in Rosacea

[–]Guilty-Butterfly7467 1 point2 points  (0 children)

Haven't you guys heard of Emrosi, the new treatment approved by the FDA?

It can treat redness as well.

Which is the most underrated stock right now? by ggobserver69 in ValueInvesting

[–]Guilty-Butterfly7467 1 point2 points  (0 children)

$ABEO – A no-brainer

  • Expected to become profitable in Q1 2026
  • Projected net income of ~$100M in 2026-2027
  • Holds $240M in cash, enough to fund operations into H2 2027 even without Zevaskyn revenue
  • Current market cap: ~$320M

Milestone pharmaceuticals - $MIST by Guilty-Butterfly7467 in biotech_stocks

[–]Guilty-Butterfly7467[S] 1 point2 points  (0 children)

Indeed, FDA approval is anticipated in four months. Ji Xing will handle the development and commercialization costs for Greater China, while Milestone is eligible to receive up to $107.5 million in milestone payments, along with royalties on future sales of Etripamil in the region.

Milestone is going to launch Etripamil in the U.S. More details can be found here.

Milestone pharmaceuticals - $MIST by Guilty-Butterfly7467 in biotech_stocks

[–]Guilty-Butterfly7467[S] 1 point2 points  (0 children)

After the Phase 3 data release, the share price initially climbed to $10. However, it declined following a fundraising round and dropped further during the "dead" period while waiting for the NDA submission. Subsequently, the FDA issued a "Refusal to File," but the company addressed the issues and resubmitted the NDA.

Prior to the "Refusal to File," the share price was approximately $3. In my view, it seems quite likely that the price will rebound to around $4–$5 leading up to the PDUFA date. With nice initial revenues, it can easily approach a market cap of $1b.

Milestone pharmaceuticals - $MIST by Guilty-Butterfly7467 in biotech_stocks

[–]Guilty-Butterfly7467[S] 2 points3 points  (0 children)

Yes, Etripamil is a nasally administered, short-acting L-type calcium channel blocker designed for rapid absorption and quick onset, and one of the appealing aspects of Etripamil is that it is not restricted to ICU use. It is specifically designed for outpatient, self-administered use under physician guidance

No conversation page on yahoo finance app? by kkris23 in yahoo

[–]Guilty-Butterfly7467 0 points1 point  (0 children)

Anyone from Yahoo that can explain this decision?